Zaremba, A., Zaremba, P., and Zahorodnia, S. (2025). A thorough insight into the life cycle of the Epstein-Barr virus. From the molecular to the organismal level. Current Research in Microbial Sciences 9, 100505. https://doi.org/10.1016/j.crmicr.2025.100505.
Zaremba, A., Zaremba, P., and Zahorodnia, S. (2025). In silico development of HASDI-G2 as a novel agent for selective recognition of the DNA sequence. Sci Rep 15, 8577. https://doi.org/10.1038/s41598-025-89967-1.
Zaremba, A.A., Zaremba, P.Y., and Zahorodnia, S.D. (2023). In silico study of HASDI (high-affinity selective DNA intercalator) as a new agent capable of highly selective recognition of the DNA sequence. Sci Rep 13, 5395. https://doi.org/10.1038/s41598-023-32595-4.
Zaremba, A., Zaremba, P., and Zahorodnia, S. (2023). De novo designed inhibitor has high affinity to four variants of the RBD of S-glycoprotein of SARS-CoV-2 - an in silico study. Journal of Biomolecular Structure and Dynamics 41, 9389–9397. https://doi.org/10.1080/07391102.2022.2141886
Zaremba, A.A., Zaremba, P.Y., and Platonov, M.O. (2023). De novo designed EBAI as a potential inhibitor of the viral protein BHRF1. Research in silico. Journal of Biomolecular Structure and Dynamics 41, 3680–3685. https://doi.org/10.1080/07391102.2022.2053746.
Zaremba, A., Zaremba, P., Muchnyk, F.V., Baranova, G., and Zahorodnia, S. (2021). In silico Identification of a Viral Surface Glycoprotein Site Suitable for the Development of Low Molecular Weight Inhibitors for Various Variants of the SARS-CoV-2. Mikrobiolohichnyi Zhurnal 84, 34–43. https://doi.org/10.15407/microbiolj84.01.034.
Zaremba, A., Zaremba, P., Budzanivska, I., and Zahorodnia, S. (2022). Patterns of the influence of vaccination on the dynamics of different SARS-CoV-2 variants spread. Two-year analysis. Bulletin of Taras Shevchenko National University of Kyiv Series Biology 89, 39–45. https://doi.org/10.17721/1728.2748.2022.89.39-45.
Zaremba, A., Zaremba, P., and Zahorodnia, S. In silico identification of a new potential drug-binding pocket on the surface of the receptor-binding domain of the SARS-CoV-2 S-glycoprotein. The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics, 1–30 November 2025, Basel, Switzerland, online.
Zaremba A., and Zahorodnia S. In silico study of ketodarolutamide as a potential inhibitor of the SARS-CoV-2 RBD interaction with human ACE2. The V Scientific Conference “Youth and Modern Problems of Microbiology and Virology”, 19-20 November 2024, Kyiv, Ukraine, P. 48.
Zaremba A., and Zahorodnia S. 3D structure data validation of the SARS-CoV-2 protein E transmembrane domain pentamer form as a potential target for drug development. Modern aspects of microbiology, virology and biotechnology in wartime and post-war period, 15-16 November 2023, Kyiv, Ukraine, P. 277-278.
Zaremba, A., Shalimov, O., Onys’ko, P., and Zahorodnia, S. In silico identification of a potential inhibitor of the SARS-CoV-2 S-glycoprotein receptor-binding domain interaction with human ACE2. 9th International Electronic Conference on Medicinal Chemistry, 1–30 November 2023, Basel, Switzerland, online.
Zaremba, A., Zaremba, P., and Zagorodnya, S. Selective DNA intercalation of massive molecules as a new method of highly specific inhibition of transcription. 6th International Electronic Conference on Medicinal Chemistry, 1–30 November 2020, Basel, Switzerland, online.
